Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

29 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Structure-guided design of pyridoclax derivatives based on Noxa / Mcl-1 interaction mode.
Hedir S, De Giorgi M, Fogha J, De Pascale M, Weiswald LB, Brotin E, Marekha B, Denoyelle C, Denis C, Suzanne P, Gautier F, Juin P, Ligat L, Lopez F, Carlier L, Legay R, Bureau R, Rault S, Poulain L, Oliveira Santos JS, Voisin-Chiret AS. Hedir S, et al. Among authors: weiswald lb. Eur J Med Chem. 2018 Nov 5;159:357-380. doi: 10.1016/j.ejmech.2018.10.003. Epub 2018 Oct 4. Eur J Med Chem. 2018. PMID: 30308410
Functional miRNA Screening Identifies Wide-ranging Antitumor Properties of miR-3622b-5p and Reveals a New Therapeutic Combination Strategy in Ovarian Tumor Organoids.
Vernon M, Lambert B, Meryet-Figuière M, Brotin E, Weiswald LB, Paysant H, Vigneron N, Wambecke A, Abeilard E, Giffard F, Louis MH, Blanc-Fournier C, Gauduchon P, Poulain L, Denoyelle C. Vernon M, et al. Among authors: weiswald lb. Mol Cancer Ther. 2020 Jul;19(7):1506-1519. doi: 10.1158/1535-7163.MCT-19-0510. Epub 2020 May 5. Mol Cancer Ther. 2020. PMID: 32371581
The lncRNA 'UCA1' modulates the response to chemotherapy of ovarian cancer through direct binding to miR-27a-5p and control of UBE2N levels.
Wambecke A, Ahmad M, Morice PM, Lambert B, Weiswald LB, Vernon M, Vigneron N, Abeilard E, Brotin E, Figeac M, Gauduchon P, Poulain L, Denoyelle C, Meryet-Figuiere M. Wambecke A, et al. Among authors: weiswald lb. Mol Oncol. 2021 Dec;15(12):3659-3678. doi: 10.1002/1878-0261.13045. Epub 2021 Jul 13. Mol Oncol. 2021. PMID: 34160887 Free PMC article.
A new pancreatic adenocarcinoma-derived organoid model of acquired chemoresistance to FOLFIRINOX: First insight of the underlying mechanisms.
Hadj Bachir E, Poiraud C, Paget S, Stoup N, El Moghrabi S, Duchêne B, Jouy N, Bongiovanni A, Tardivel M, Weiswald LB, Vandepeutte M, Beugniez C, Escande F, Leteurtre E; OrgaRES consortium; Poulain L, Lagadec C, Pigny P, Jonckheere N, Renaud F, Truant S, Van Seuningen I, Vincent A. Hadj Bachir E, et al. Among authors: weiswald lb. Biol Cell. 2022 Jan;114(1):32-55. doi: 10.1111/boc.202100003. Epub 2021 Oct 16. Biol Cell. 2022. PMID: 34561874
Structural revision of the Mcl-1 inhibitor MIM1: synthesis and biological studies on ovarian cancer cells with evaluation of designed analogues.
Paysant H, Hedir S, Justaud F, Weiswald LB, El Dine AN, Soulieman A, Hachem A, Elie N, Brotin E, Denoyelle C, Bignon J, Roussi F, Jouanne M, Tasseau O, Roisnel T, Voisin-Chiret AS, Grée R, Levoin N, Poulain L. Paysant H, et al. Among authors: weiswald lb. Org Biomol Chem. 2021 Oct 27;19(41):8968-8987. doi: 10.1039/d1ob01521d. Org Biomol Chem. 2021. PMID: 34596646 Free article.
Drug Repurposing: Deferasirox Inhibits the Anti-Apoptotic Activity of Mcl-1.
Bourafai-Aziez A, Benabderrahmane M, Paysant H, Weiswald LB, Poulain L, Carlier L, Ravault D, Jouanne M, Coadou G, Oulyadi H, Voisin-Chiret AS, Sopková-de Oliveira Santos J, Sebban M. Bourafai-Aziez A, et al. Among authors: weiswald lb. Drug Des Devel Ther. 2021 Dec 15;15:5035-5059. doi: 10.2147/DDDT.S323077. eCollection 2021. Drug Des Devel Ther. 2021. PMID: 34949914 Free PMC article.
A phase II study of Navitoclax (ABT-263) as single agent in women heavily pretreated for recurrent epithelial ovarian cancer: The MONAVI - GINECO study.
Joly F, Fabbro M, Follana P, Lequesne J, Medioni J, Lesoin A, Frenel JS, Abadie-Lacourtoisie S, Floquet A, Gladieff L, You B, Gavoille C, Kalbacher E, Briand M, Brachet PE, Giffard F, Weiswald LB, Just PA, Blanc-Fournier C, Leconte A, Clarisse B, Leary A, Poulain L. Joly F, et al. Among authors: weiswald lb. Gynecol Oncol. 2022 Apr;165(1):30-39. doi: 10.1016/j.ygyno.2022.01.021. Epub 2022 Feb 2. Gynecol Oncol. 2022. PMID: 35123771 Clinical Trial.
29 results